Related Experiment Video
Updated: Jul 5, 2025
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Antithrombotic Therapy Optimization in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary
Felice Gragnano1,2, Antonio Capolongo1,2, Antonio Micari3
1Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli", 81100 Caserta, Italy.
Insights
Managing atrial fibrillation (AF) patients after percutaneous coronary intervention (PCI) requires balancing antithrombotic therapy to prevent clots and bleeding. Current strategies involve short triple therapy followed by dual therapy to mitigate risks.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Medicine
Background:
- Antithrombotic management for atrial fibrillation (AF) patients undergoing percutaneous coronary intervention (PCI) presents significant clinical challenges.
- Triple antithrombotic therapy (TAT), combining dual antiplatelet therapy (DAPT) and oral anticoagulation (OAC), offers anti-ischemic benefits but elevates bleeding risk.
Purpose of the Study:
- To review evidence on post-procedural antithrombotic therapies for non-valvular AF patients undergoing PCI.
- To discuss the complexities in decision-making for antithrombotic strategies, particularly in elderly patients and those with comorbidities.
Main Methods:
- Review of randomized clinical trials and meta-analyses.
- Analysis of pharmacological approaches including TAT, dual antithrombotic therapy (DAT), and OAC monotherapy.
Main Results:
- TAT is typically limited to one week post-PCI, followed by aspirin withdrawal and DAT (OAC + clopidogrel) for 6-12 months.
- This approach aims to reduce bleeding risk while maintaining anti-ischemic efficacy.
Conclusions:
- The optimal antithrombotic strategy balances ischemic and bleeding risks, especially in complex patient populations.
- Evidence from clinical trials guides the transition from TAT to DAT and OAC monotherapy in AF patients post-PCI.
Abstract:
The antithrombotic management of patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) poses numerous challenges. Triple antithrombotic therapy (TAT), which combines dual antiplatelet therapy (DAPT) with oral anticoagulation (OAC), provides anti-ischemic protection but increases the risk of bleeding. Therefore, TAT is generally limited to a short phase (1 week) after PCI, followed by aspirin withdrawal and continuation of 6-12 months of dual antithrombotic therapy (DAT), comprising OAC plus clopidogrel, followed by OAC alone. This pharmacological approach has been shown to mitigate bleeding risk while preserving adequate anti-ischemic efficacy. However, the decision-making process remains complex in elderly patients and those with co-morbidities, significantly influencing ischemic and bleeding risk. In this review, we discuss the available evidence in this area from randomized clinical trials and meta-analyses for post-procedural antithrombotic therapies in patients with non-valvular AF undergoing PCI.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...